Evaluasi Parameter Laboratorium Klinis pada Pasien Diabetes dan Diabetes dengan Hipertensi Pasca Vaksinasi Vaksin Sinovac
Authors: Ngarso Sofia , Ramatillah Diana Laila , Huri Hasniza Zaman 
Published: October 2024

ABSTRACT During the COVID-19 pandemic, people with diabetes and hypertension are especially vulnerable to this virus. Of 1488 cases, 50.5% of patients had hypertension, 34.5% had diabetes, with mortality rates of 13.2% and 11.6%, respectively. This study aims to evaluate the clinical laboratory parameters of diabetes and hypertensive diabetes patients who have been vaccinated with Sinovac Vaccine. This study used retrospective and prospective cohort methods with convenience sampling. Inclusion criteria included patients over 18 years of age who were diagnosed with diabetes and diabetes with hypertension, had been vaccinated with two doses of Sinovac, and had filled out informed consent. From the 300 research samples, there were 169 women (56.3%). The majority of patients (94.4%) were over 40 years old, with 36.0% having comorbid DM hypertension with cholesterol, and 26.6% were smokers. The results of the analysis showed that age (P = 0.009), gender (P = 0.000), BMI (P = 0.000), and time of diagnosis (P = 0.000) were significantly correlated with EGFR clinical results. BMI (P=0.007) was also significantly associated with creatinine. Diabetes medication use showed significant association with GDS (P = 0.000) and HbA1c (P = 0.000). There is a significant relationship between gender, age, BMI, and time diagnosed with EGFR. Patients with a diagnosis period of more than 10 years suffer from stage 3 kidney failure reaching 9% and stages 4 and 5 reaching 4%. The use of metformin, sulfonyl urea, insulin glulisine, and insulin glargine provides a controlled effect on GDS and HbA1c. Keywords: Diabetes, Hypertension, Laboratory, Sinovac, Sosiodemography ABSTRAK Selama pandemi COVID-19, penderita diabetes dan hipertensi sangat rentan terhadap virus ini. Dari 1488 kasus, 50,5% pasien memiliki hipertensi, 34,5% menderita diabetes, dengan angka kematian masing-masing 13,2% dan 11,6%. Penelitian ini bertujuan mengevaluasi hasil klinis laboratorium pasien Diabetes dan Diabetes dengan Hipertensi yang telah divaksinasi dengan Vaksin Sinovac. Penelitian ini menggunakan metode kohort retrospektif dan prospektif dengan pengambilan sampel secara convenience sampling. Kriteria inklusi mencakup pasien berusia di atas 18 tahun yang terdiagnosis diabetes dan diabetes dengan hipertensi, telah divaksinasi Vaksin Sinovac dua dosis, dan telah mengisi informed consent. Dari 300 sampel penelitian, perempuan berjumlah 169 (56.3%). Mayoritas pasien 94.4% berusia di atas 40 tahun dengan 36,0% memiliki komorbiditas DM hipertensi dengan kolesterol, dan 26.6% adalah perokok. Hasil analisis menunjukkan bahwa usia (P = 0,009), jenis kelamin (P = 0,000), IMT (P = 0,000), dan lama terdiagnosis (P=0,000) berkorelasi secara signifikan dengan hasil klinis EGFR. IMT (P-0,007) juga berhubungan secara signifikan dengan hasil klinis kreatinin. Penggunaan obat diabetes menunjukkan hubungan yang signifikan dengan hasil klinis GDS (P = 0,000) dan HbA1c (P = 0,000). Terdapat hubungan yang signifikan antara jenis kelamin, usia, Indeks Masa Tubuh (IMT), dan lama terdiagnosis dengan gagal ginjal (EGFR). Pasien dengan lama terdiagnosis lebih dari 10 tahun menderita gagal ginjal stadium 3 mencapai 9% dan stadium 4 dan 5 mencapai 4%. Penggunaan obat diabetes, metformin, sulfonil urea, insulin glulisine, dan insulin glargine memberikan efek terkontrol pada GDS dan HbA1c. Kata Kunci: Diabetes, Hipertensi, Laboratorium, Sinovac, Sosiodemografi